Table of Contents
Abstract
Polymorphism — the ability of a compound to exist in multiple crystalline forms — is a critical but often overlooked quality attribute in pharmaceutical intermediates. Different polymorphs can exhibit dramatically different solubility, stability, and bioavailability. The 1998 Ritonavir crisis, where a new crystal form (Form II) emerged post-launch and caused market withdrawal with losses exceeding $250 million, remains the industry’s defining cautionary tale. This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
McCrone’s classic 1965 definition describes a polymorph as “a solid crystalline phase of a given compound resulting from the possibility of at least two different arrangements of the molecules of that compound in the solid state.” In simpler terms: the same molecule can pack into different crystal structures, and each structure can have distinctly different physical properties.
For pharmaceutical intermediates, these differences are not academic. They directly affect:
Property | Why It Matters for Intermediates |
Solubility | Different polymorphs can differ in solubility by 2–5×, affecting downstream API yield and purification efficiency |
Stability | Metastable forms may convert to stable forms during storage or processing, changing the material’s behavior unexpectedly |
Melting point | Polymorphs can differ by 2–20°C in melting point, affecting crystallization and drying parameters |
Dissolution rate | Directly impacts bioavailability if the intermediate is close to the final API in the synthesis chain |
Filterability & flow | Crystal habit (needle vs. plate vs. prism) affects filtration time, drying efficiency, and handling |
Most discussions of polymorphism focus on APIs. But intermediates matter too — especially late-stage intermediates that are one or two steps from the API. If the intermediate’s solid form changes between batches, the downstream crystallization yield, impurity profile, and process reproducibility all shift. Knowing how to read a COA means knowing whether your supplier controls solid form — or ignores it.
In 1996, Abbott Laboratories launched Ritonavir (Norvir®), a protease inhibitor for HIV. During development, only one crystalline form (Form I) was known. Extensive polymorph screening failed to find any others.
In 1998 — approximately 18 months after launch — quality control began detecting dissolution failures in certain lots. Investigation revealed a second crystalline form, Form II, that had never been observed during development. Form II was approximately 50% less soluble than Form I. Worse, Form II was thermodynamically more stable: once it appeared, it acted as a seed crystal and spread to every manufacturing facility. Form I became impossible to produce in those contaminated environments.
The drug was withdrawn from the market in all but a liquid formulation. Abbott lost an estimated $250 million in recalled inventory, lost sales, and manufacturing facility write-offs. (Chemburkar et al., Org. Process Res. Dev., 2000, 4(5), 413–417)
The Ritonavir case is not ancient history. It fundamentally changed how the pharmaceutical industry approaches solid form screening. Today, ICH Q6A, FDA guidance, and Chinese CDE guidelines all require systematic polymorph assessment. The question for intermediate buyers is: does your supplier follow these expectations?
ICH Q6A (Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products) includes Decision Tree #4, which provides a framework for determining when polymorph control is needed in drug substance specifications.
The decision tree logic is sequential:
The FDA’s 2007 guidance, ANDAs: Pharmaceutical Solid Polymorphism, extends this framework to generic drugs with three additional decision trees covering drug substance specifications, drug product monitoring, and sameness determination.
In China, the CDE released the Technical Guidelines for Polymorph Research of Chemical Innovative Drugs (Trial) in January 2026, aligning domestic requirements with ICH Q6A. The Chinese Pharmacopoeia 2025 edition includes Chapter 9015 (Guidelines for Polymorph Research and Quality Control of Drugs), which specifies XRPD as the primary method for polymorph identification and quantification.
For intermediate buyers, the practical takeaway: if your supplier cannot tell you whether polymorph control applies to your material — or cannot produce XRPD data when asked — that is a gap that may surface during regulatory filing or scale-up.
Most intermediate COAs report “Appearance: White crystalline powder” and stop there. But “white crystalline powder” tells you nothing about which polymorph you received. Here are five red flags:
X-ray powder diffraction (XRPD) is the regulatory gold standard for polymorph identification. Each polymorph produces a unique diffraction pattern. If the COA does not include XRPD data — or at least a reference to an internal XRPD specification — the supplier is not controlling solid form.
Appearance alone cannot distinguish polymorphs. A supplier who reports appearance but not crystal form is either not testing for polymorphism or not reporting it. Either way, you cannot verify what you received.
Differential Scanning Calorimetry (DSC) can detect polymorph differences through melting point and enthalpy of fusion. But a DSC thermogram without a reference comparison is just a curve. The COA should state which polymorph the DSC pattern matches.
If the melting point drifts between batches — even within specification — it may indicate polymorph conversion. A supplier who does not flag this is either unaware or choosing not to investigate.
Polymorph outcome depends on crystallization conditions: solvent system, cooling rate, seeding, and agitation. If the supplier cannot describe the crystallization process or confirm it is controlled, polymorph consistency cannot be guaranteed.
These gaps connect directly to other quality dimensions. If a supplier skips elemental impurity testing (ICH Q3D) and polymorph control simultaneously, the overall quality system may have systemic gaps.
Question | What a Good Answer Sounds Like | |
1 | Has polymorph screening been performed on this intermediate? | “Yes, we identified [N] polymorphic forms and designated Form [X] as the target. XRPD patterns are available on request.” |
2 | Which analytical method confirms the polymorph on each batch? | “XRPD with reference pattern comparison” or “DSC with defined melting onset range matching Form [X].” |
3 | What crystallization conditions are controlled to ensure polymorph consistency? | “Crystallization from [solvent system] at [temperature range] with [seeding protocol]. Cooling rate is controlled at [rate].” |
Suppliers who answer these questions with specifics — not “we comply with standards” — are the ones who actually control their process. This is especially important for intermediates with chiral purity requirements, since polymorph transitions can co-occur with stereochemical changes during scale-up.
Polymorph stability is not static. Temperature and humidity shifts during storage and shipping can trigger form conversion — especially for metastable forms. A hygroscopic intermediate stored at 60% humidity may absorb moisture and undergo solvent-mediated phase transformation, converting to a hydrate or a different anhydrous form.
This means the polymorph you receive may not be the polymorph you have three months later. If your supplier only controls polymorph at release — without stability data demonstrating form retention through the retest period — the COA’s polymorph information has an expiration date.
Polymorphism is not an API-only concern. For late-stage intermediates, uncontrolled solid form can cause downstream yield loss, impurity spikes, filing delays, and batch rejection. The Ritonavir case cost Abbott $250 million — not because the molecule was wrong, but because the crystal form was uncontrolled.
As a buyer, your leverage is simple: ask for XRPD data. Ask about crystallization control. Ask about polymorph stability. If the supplier cannot answer, the risk is yours to carry — and the cost of getting it wrong, as Abbott learned, can be measured in hundreds of millions.
This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
This guide explains the four element classes, the 30% control threshold that determines whether routine testing is required, the difference between ICP-MS and ICP-OES analytical methods, and five red flags on supplier COAs that signal inadequate elemental impurity control.
This guide explains what ee% measures, why it differs from optical purity, how chiral HPLC validates stereochemical integrity, and which COA fields separate genuine process control from cosmetic data.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.